Daniel José García-Domínguez

11PUBLICATIONS
42CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 28, 2025
EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism.

Joaquin Olmedo-Pelayo, Esperanza Granado-Calle, Daniel Delgado-Bellido

|Jan 23, 2024
Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.

Daniel J García-Domínguez, Soledad López-Enríquez, Gonzalo Alba

|Mar 29, 2023
Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells.

María Luisa Sánchez-León, Carlos Jiménez-Cortegana, Silvia Silva Romeiro

|Dec 23, 2022
Obesity and Risk for Lymphoma: Possible Role of Leptin.

Carlos Jiménez-Cortegana, Lourdes Hontecillas-Prieto, Daniel J García-Domínguez

|Nov 11, 2022
Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies.

Sara Sánchez-Molina, Elisabet Figuerola-Bou, Víctor Sánchez-Margalet

|Jun 21, 2022
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.

Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández

Pageof 2

Frequent Collaborators

8 joint publications

Lourdes Hontecillas-Prieto

6 joint publications

Víctor Sánchez-Margalet

5 joint publications

Enrique de Álava Casado

4 joint publications

Elisabet Figuerola-Bou